Agios pharmaceuticals, inc.AGIO.US Overview

US StockHealthcare

(No presentation for AGIO)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

AGIO Overall Performance

AGIO AI Analysis & Strategy

AGIO Recent Performance

1.47%

Agios pharmaceuticals, inc.

0.81%

Avg of Sector

-1.14%

S&P500

AGIO PowerScanner

AGIO Key Information

AGIO Valuation Metrics

AGIO Earnings Table

AGIO Profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.